# Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

> **NCT04720131** · PHASE2 · COMPLETED · sponsor: **Beijing Friendship Hospital** · enrollment: 28 (actual)

## Conditions studied

- Biliary Tract Cancer
- Anti-PD-1 Therapy
- Targeted Molecular Therapy
- Capecitabine

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** apatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04720131
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720131, "Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04720131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*